Comparative Effects of GLP-1 Agonists, Sleeve Gastrectomy and Roux-en-Y Gastric Bypass on Diabetes Mellitus Outcomes.

IF 5.2 2区医学 Q1 ENDOCRINOLOGY & METABOLISM Current Diabetes Reports Pub Date : 2024-12-01 Epub Date: 2024-09-26 DOI:10.1007/s11892-024-01554-2

Tasiyah Essop, Kyle Tran, Amanda C Purdy, Shaun C Daly

{"title":"Comparative Effects of GLP-1 Agonists, Sleeve Gastrectomy and Roux-en-Y Gastric Bypass on Diabetes Mellitus Outcomes.","authors":"Tasiyah Essop, Kyle Tran, Amanda C Purdy, Shaun C Daly","doi":"10.1007/s11892-024-01554-2","DOIUrl":null,"url":null,"abstract":"Purpose of review: The purpose of this review is to assess the effects of glucagon-like peptide-1 (GLP-1) agonists, sleeve gastrectomy (SG), and Roux-en-Y gastric bypass (RYGB) on type 2 diabetes mellitus (T2DM) remission. This review explores the efficacy, safety, and durability of these surgical and medical modalities of diabetes management.Recent findings: Studies have shown that GLP-1 agonists achieve higher rates of T2DM remission compared to standard glucose-lowering medications and lifestyle changes. In addition to weight loss, bariatric surgery has been found to be highly effective in treating and inducing remission of T2DM. Studies suggest that post-surgical patients see enhanced glycemic control. Both surgical interventions and GLP1 agonists are effective in achieving T2DM remission. Long-term follow-up and randomized controlled trials comparing bariatric surgery and GLP-1 agonists are necessary to evaluate their relative effectiveness in T2DM control. Further research is also needed to assess the combined effects of these treatment modalities.","PeriodicalId":10898,"journal":{"name":"Current Diabetes Reports","volume":" ","pages":"273-289"},"PeriodicalIF":5.2000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Diabetes Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11892-024-01554-2","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/26 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: The purpose of this review is to assess the effects of glucagon-like peptide-1 (GLP-1) agonists, sleeve gastrectomy (SG), and Roux-en-Y gastric bypass (RYGB) on type 2 diabetes mellitus (T2DM) remission. This review explores the efficacy, safety, and durability of these surgical and medical modalities of diabetes management.

Recent findings: Studies have shown that GLP-1 agonists achieve higher rates of T2DM remission compared to standard glucose-lowering medications and lifestyle changes. In addition to weight loss, bariatric surgery has been found to be highly effective in treating and inducing remission of T2DM. Studies suggest that post-surgical patients see enhanced glycemic control. Both surgical interventions and GLP1 agonists are effective in achieving T2DM remission. Long-term follow-up and randomized controlled trials comparing bariatric surgery and GLP-1 agonists are necessary to evaluate their relative effectiveness in T2DM control. Further research is also needed to assess the combined effects of these treatment modalities.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

GLP-1激动剂、袖状胃切除术和Roux-en-Y胃旁路术对糖尿病疗效的比较效果。

综述目的：本综述旨在评估胰高血糖素样肽-1（GLP-1）激动剂、袖状胃切除术（SG）和Roux-en-Y胃旁路术（RYGB）对2型糖尿病（T2DM）缓解的影响。本综述探讨了这些外科和内科糖尿病治疗方法的疗效、安全性和持久性：研究表明，与标准降糖药物和改变生活方式相比，GLP-1 促效剂可实现更高的 T2DM 缓解率。除减轻体重外，减肥手术对治疗和缓解 T2DM 也非常有效。研究表明，手术后患者的血糖控制得到加强。手术干预和 GLP1 激动剂都能有效缓解 T2DM。有必要对减肥手术和 GLP-1 激动剂进行长期跟踪和随机对照试验，以评估它们在控制 T2DM 方面的相对效果。此外，还需要进一步的研究来评估这些治疗方式的综合效果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Current Diabetes Reports 医学 -

CiteScore

9.80

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： The goal of this journal is to publish cutting-edge reviews on subjects pertinent to all aspects of diabetes epidemiology, pathophysiology, and management. We aim to provide incisive, insightful, and balanced contributions from leading experts in each relevant domain that will be of immediate interest to a wide readership of clinicians, basic scientists, and translational investigators. We accomplish this aim by appointing major authorities to serve as Section Editors in key subject areas across the discipline. Section Editors select topics to be reviewed by leading experts who emphasize recent developments and highlight important papers published over the past year on their topics, in a crisp and readable format. We also provide commentaries from well-known figures in the field, and an Editorial Board of internationally diverse members suggests topics of special interest to their country/region and ensures that topics are current and include emerging research.